The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFNγ production by PBMC

Journal of Autoimmunity

Volumn 44, Issue , 2013, Pages 8-12

  Myhr, Courtney B ^a   Hulme, Maigan A ^a   Wasserfall, Clive H ^a   Hong, Peter J ^a   Lakshmi, Priya Saikumar ^a   Schatz, Desmond A ^a   Haller, Michael J ^a   Brusko, Todd M ^a   Atkinson, Mark A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmunity; Celiac disease; Genome wide association; IL 18; NK cells; Type 1 diabetes

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 18 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MICRORNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CELIAC DISEASE; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; GENE EXPRESSION; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84881375632     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.06.001     Document Type: Article

References (21)

1. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
2. Patterson C.C., Dahquist G.G., Gyurus E., Green A., Soltesz G., Grp E.S. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373:2027-2033.
3. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
4. Greenbaum C., Atkinson M.A. Persistence is the twin sister of excellence an important lesson for attempts to prevent and reverse type 1 diabetes. Diabetes 2011, 60:693-694.
5. Van Belle T.L., Coppieters K.T., Von Herrath M.G. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiological Reviews 2011, 91:79-118.
6. Skyler J.S., Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 2011, 60:1-8.
7. Dinarello C.A. IL-18: a T-H1-inducing, proinflammatory cytokine and new member of the IL-1 family. Journal of Allergy and Clinical Immunology 1999, 103:11-24.
8. Hoeve M.A., Savage N.D.L., de Boer T., Langenberg D.M.L., Malefyt R.D., Ottenhoff T.H.M., et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. European Journal of Immunology 2006, 36:661-670.
9. Leite-De-Moraes M.C., Hameg A., Pacilio M., Koezuka Y., Taniguchi M., Van Kaer L., et al. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. Journal of Immunology 2001, 166:945-951.
10. Oertli M., Sundquist M., Hitzler I., Engler D.B., Arnold I.C., Reuter S., et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. Journal of Clinical Investigation 2012, 122:1082-1096.
11. Rothe H., Hausmann A., Casteels K., Okamura H., Kurimoto M., Burkart V., et al. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. Journal of Immunology 1999, 163:1230-1236.
12. Oikawa Y., Shimada A., Kasuga A., Morimoto J., Osaki T., Tahara H., et al. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. Journal of Immunology 2003, 171:5865-5875.
13. Yoshimoto T., Takeda K., Tanaka T., Ohkusu K., Kashiwamura S., Okamura H., et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. Journal of Immunology 1998, 161:3400-3407.
14. Todd J.A., Smyth D.J., Plagnol V., Walker N.M., Cooper J.D., Downes K., et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. New England Journal of Medicine 2008, 359:2767-2777.
15. Zhernakova A., Elbers C.C., Ferwerda B., Romanos J., Trynka G., Dubois P.C., et al. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. American Journal of Human Genetics 2010, 86:970-977.
16. Hunt K.A., Zhernakova A., Turner G., Heap G.A., Franke L., Bruinenberg M., et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nature Genetics 2008, 40:395-402.
17. Yang J.F., Murphy T.L., Ouyang W.J., Murphy K.M. Induction of interferon-gamma production in Th1 CD4(+) T cells: evidence for two distinct pathways for promoter activation. European Journal of Immunology 1999, 29:548-555.
18. Qin H.L., Lee I.F., Panagiotopoulos C., Wang X.X., Chu A.D., Utz P.J., et al. Natural killer cells from children with type 1 diabetes have defects in NKG2D-dependent function and signaling. Diabetes 2011, 60:857-866.
19. Wang K., Baldassano R., Zhang H., Qu H.Q., Imielinski M., Kugathasan S., et al. Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Human Molecular Genetics 2010, 19:2059-2067.
20. van der Werf N., Kroese F.G.M., Rozing J., Hillebrands J.L. Viral infections as potential triggers of type 1 diabetes. Diabetes Metabolism Research 2007, 23:169-183.
21. Winkler C., Krumsiek J., Lempainen J., Achenbach P., Grallert H., Giannopoulou E., et al. Astrategy for combining minor genetic susceptibility genes to improveprediction of disease in type 1 diabetes. Genes and Immunity 2012, 13:549-555.